AbbVie Stock Hits Day Low of $203.06 Amid Price Pressure

AbbVie, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock declining by 6.68%. The stock reached an intraday low of USD 203.06, reflecting a challenging performance compared to the broader market, as the S&P 500 only fell by 1.51% during the same period. Over the past week, AbbVie has seen a decline of 9.93%, and its performance over the last month shows a decrease of 10.34%. Year-to-date, the stock is down 10.25%, contrasting sharply with the S&P 500's decline of 4.95%. Despite a positive three-year performance of 32.97%, the stock's one-year return stands at -4.11%, significantly underperforming the S&P 500's gain of 14.9%. AbbVie’s financial metrics indicate a high debt-to-equity ratio, raising concerns about its long-term fundamental strength. The company reported a low inventory turnover ratio of 3.69 times and cash and equivalents at USD 11,643 million, alongside a high quarterly interest expense of USD 782 million. These factors contribute to a perception of increased risk in the stock's current valuation.